Using machine learning, a form of artificial intelligence, researchers were able to cluster people with Huntington’s disease into three…
Articles by Marisa Wexler, MS
Austedo XR, a new extended-release formulation of Austedo (deutetrabenazine) has been approved by the U.S. Food and Drug Administration (FDA) to treat…
Treatment with antioxidant compounds called fullerenols showed neuroprotective effects in a fruit fly model of Huntington’s disease, particularly at…
In Huntington’s disease, neurodegeneration in a brain region called the striatum differs not only across different types of neurons, but…
Branaplam (LMI070), an experimental oral therapy for Huntington’s disease that’s currently in early clinical trials, reduces levels of the…
Palliative care training for all clinicians on an interdisciplinary team can increase the number of discussions about advanced care planning…
Many U.S. clinics treating people with Huntington’s disease reported difficulties in accessing needed professionals — such as genetic counselors,…
Reduced volumes of gray matter in certain regions of the brain are tied to poorer quality of life in people…
Due to possible side effects, dosing is being paused in the Phase 2 VIBRANT-HD clinical trial of oral branaplam (LMI070) in adults…
Long-term trials of interventions to promote physical activity for people with Huntington’s disease are feasible, with a “nested trial” approach…